{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:41:56Z","timestamp":1781905316532,"version":"3.54.5"},"reference-count":45,"publisher":"Informa UK Limited","issue":"8","funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2023,9,14]]},"DOI":"10.1080\/14737167.2023.2240515","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T06:16:02Z","timestamp":1690179362000},"page":"879-889","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Implementing outcomes-based risk-sharing agreements: an integrative review of applications in blood cancer in the UK and beyond"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0042-8547","authenticated-orcid":false,"given":"Diana Beatriz","family":"Bayani","sequence":"first","affiliation":[{"name":"Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Republic of Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-1801","authenticated-orcid":false,"given":"Hwee Lin","family":"Wee","sequence":"additional","affiliation":[{"name":"Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Republic of Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200867"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100028"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01077-3"},{"key":"e_1_3_6_6_1","first-page":"11","article-title":"The oncology pipeline overview: recent approvals and near-term drugs","volume":"14","year":"2021","unstructured":"The oncology pipeline overview: recent approvals and near-term drugs. J Hematol Oncol Phram. 2021;14(4):11. https:\/\/www.ahdbonline.com\/issues\/2021\/december-2021-vol-14-no-4\/3194-the-oncology-pipeline-overview-recent-approvals-and-near-term-drugs","journal-title":"J Hematol Oncol Phram"},{"key":"e_1_3_6_7_1","volume-title":"Global oncology trends 2021: outlook to 2025","year":"2021","unstructured":"Global oncology trends 2021: outlook to 2025. North Carolina, USA: IQVIA Institute for Human Data Science; 2021."},{"issue":"8","key":"e_1_3_6_8_1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jval.2017.03.011","article-title":"Towards integrated health technology assessment for improving decision making in selected countries","volume":"20","author":"Oortwijn W","year":"2017","unstructured":"Oortwijn W, Determann D, Schiffers K, et al. Towards integrated health technology assessment for improving decision making in selected countries. Value Health. 2017 Sep;20(8):1121\u20131130.","journal-title":"Value Health"},{"issue":"3","key":"e_1_3_6_9_1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jval.2016.10.014","article-title":"Health Technology Assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland","volume":"20","author":"Allen N","year":"2017","unstructured":"Allen N, Walker SR, Liberti L, et al. Health Technology Assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland. Value Health. 2017 Mar;20(3):320\u2013328.","journal-title":"Value Health"},{"issue":"3","key":"e_1_3_6_10_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40258-020-00634-0","article-title":"Which criteria are considered and how are they evaluated in health technology assessments? A review of methodological guidelines used in Western and Asian Countries","volume":"19","author":"Wang Y","year":"2021","unstructured":"Wang Y, Qiu T, Zhou J, et al. Which criteria are considered and how are they evaluated in health technology assessments? A review of methodological guidelines used in Western and Asian Countries. Appl Health Econ Health Policy. 2021 May;19(3):281\u2013304.","journal-title":"Appl Health Econ Health Policy"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-S1-58"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28040236"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.04.011"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2020.02.002"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.10.1028"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00943-1"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-017-0044-1"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00171"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08437-w"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2381468321990404"},{"key":"e_1_3_6_21_1","volume-title":"Global oncology trends 2019: therapeutics, clinical development and health system implications","year":"2019","unstructured":"Global oncology trends 2019: therapeutics, clinical development and health system implications. North Carolina, USA: IQVIA Institute for Human Data Science; 2019."},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1679-45082010rw1134"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.999220"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.771966"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.940886"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.940371"},{"issue":"1","key":"e_1_3_6_27_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40273-021-01070-1","article-title":"The challenges of outcomes-based contract implementation for medicines in Europe","volume":"40","author":"Bohm N","year":"2022","unstructured":"Bohm N, Bermingham S, Grimsey Jones F, et al. The challenges of outcomes-based contract implementation for medicines in Europe. PharmacoEconomics. 2022 Jan;40(1):13\u201329.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"e_1_3_6_28_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.healthpol.2020.02.002","article-title":"Risk sharing in managed entry agreements\u2014A review of the Swedish experience","volume":"124","author":"Andersson E","year":"2020","unstructured":"Andersson E, Svensson J, Persson U, et al. Risk sharing in managed entry agreements\u2014A review of the Swedish experience. Health Policy. 2020 Apr;124(4):404\u2013410.","journal-title":"Health Policy"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1017\/S026646231900031X"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0633-6"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462317001106"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.09.007"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta16460"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462309990882"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2010.02.005"},{"key":"e_1_3_6_36_1","volume-title":"Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies","author":"National Insitute for Health and Care Excellence","year":"2019","unstructured":"National Insitute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. London (UK): National Institute for Health and Care Excellence; 2019."},{"key":"e_1_3_6_37_1","volume-title":"Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies","author":"National Insitute for Health and Care Excellence","year":"2019","unstructured":"National Insitute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. London (UK): National Institute for Health and Care Excellence; 2019."},{"key":"e_1_3_6_38_1","volume-title":"Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma","author":"National Insitute for Health and Care Excellence","year":"2018","unstructured":"National Insitute for Health and Care Excellence. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. London (UK): National Institute for Health and Care Excellence; 2018."},{"key":"e_1_3_6_39_1","volume-title":"Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia","author":"National Insitute for Health and Care Excellence","year":"2020","unstructured":"National Insitute for Health and Care Excellence. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. London (UK): National Institute for Health and Care Excellence; 2020."},{"key":"e_1_3_6_40_1","volume-title":"Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years","author":"National Insitute for Health and Care Excellence","year":"2018","unstructured":"National Insitute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. London (UK): National Institute for Health and Care Excellence; 2018."},{"key":"e_1_3_6_41_1","volume-title":"Venetoclax for treating chronic lymphocytic leukaemia","author":"National Insitute for Health and Care Excellence","year":"2017","unstructured":"National Insitute for Health and Care Excellence. Venetoclax for treating chronic lymphocytic leukaemia. London (UK): National Institute for Health and Care Excellence; 2017."},{"key":"e_1_3_6_42_1","volume-title":"Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma","author":"National Insitute for Health and Care Excellence","year":"2020","unstructured":"National Insitute for Health and Care Excellence. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. London (UK): National Institute for Health and Care Excellence; 2020."},{"key":"e_1_3_6_43_1","volume-title":"Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma","author":"National Insitute for Health and Care Excellence","year":"2019","unstructured":"National Insitute for Health and Care Excellence. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. London (UK): National Institute for Health and Care Excellence; 2019."},{"key":"e_1_3_6_44_1","volume-title":"Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma","author":"National Insitute for Health and Care Excellence","year":"2018","unstructured":"National Insitute for Health and Care Excellence. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. London (UK): National Institute for Health and Care Excellence; 2018."},{"key":"e_1_3_6_45_1","volume-title":"Bortezomib monotherapy for relapsed multiple myeloma","author":"National Insitute for Health and Care Excellence","year":"2007","unstructured":"National Insitute for Health and Care Excellence. Bortezomib monotherapy for relapsed multiple myeloma. London (UK): National Institute for Health and Care Excellence; 2007."},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00369-9"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-014-0093-x"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2023.2240515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:30:07Z","timestamp":1695637807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2023.2240515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,9,14]]}},"alternative-id":["10.1080\/14737167.2023.2240515"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2023.2240515","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}